Veselska R et al.: Comparative Analysis of Putative Prognostic and Predictive Markers in Neuroblastomas: High Expression of PBX1 Is Associated with a Poor Response to Induction Therapy. Frontiers in Oncology 9, Art. No. 1221, 2019.
Neradil J et al.: Phospho-Protein Arrays as Effective Tools for Screening Possible Targets for Kinase Inhibitors and Their Use in Precision Pediatric Oncology. Frontiers in Oncology 9, Art. No. 930, 2019.
Dobrotkova V et al.: Prediction of neuroblastoma cell response to treatment with natural or synthetic retinoids using selected protein biomarkers. PLoS ONE 14, Art. No. e0218269, 2019.
Gomes S et al.: New inhibitor of the TAp73 interaction with MDM2 and mutant p53 with promising antitumor activity against neuroblastoma. Cancer Letters 446, 90-102, 2019.
Skoda J et al.: Pharmacological targeting of mitochondria in cancer stem cells: An ancient organelle at the crossroad of novel anti-cancer therapies. Pharmacological Research 139, 298-313, 2019.
Dobrotkova V et al.: Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy. BMC Cancer 18, Art. No. 1059, 2018.
Sramek M et al.: Effects of sunitinib and other kinase inhibitors on cells harboring a PDGFRB mutation associated with infantile myofibromatosis. International Journal of Molecular Sciences 19, Art. No. E2599, 2018.
Skoda J and Veselska R: Cancer stem cells in sarcomas: Getting to the stemness core. Biochimica et Biophysica Acta – General Subjects 1862, 2134-2139, 2018.
Chlapek P et al.: Why differentiation therapy sometimes fails: molecular mechanisms of resistance to retinoids. International Journal of Molecular Sciences 19, Art. No. E132, 2018.
Chlapek P et al.: Uniformity under in vitro conditions: Changes in the phenotype of cancer cell lines derived from different medulloblastoma subgroups. PLoS ONE 12, Art. No. e0172552, 2017.